

***Fusobacterium nucleatum* is associated with worse prognosis in Lauren´s diffuse type gastric cancer patients**

Ellen Teresa Boehm¹, Cosima Thon¹, Juozas Kupcinskas^{2,3}, Ruta Steponaitiene², Jurgita Skieceviciene², Ali Canbay¹, Peter Malfertheiner¹ and Alexander Link¹

¹Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University Magdeburg, Magdeburg, Germany

²Institute for Digestive Research, Lithuanian University of Health Sciences, Kaunas, Lithuania

³Department of Gastroenterology, Lithuanian University of Health Sciences, Kaunas, Lithuania

Corresponding author

Alexander Link, M.D., Ph.D.

Department of Gastroenterology, Hepatology and Infectious Diseases

Otto-von-Guericke University

Leipziger Str. 44

39120 Magdeburg, Germany

Phone: +49-391-6713745

Fax: +49-391-6713105

Email: alinkmail@gmail.com or alexander.link@med.ovgu.de

Supplementary Table S1: Overview of samples and methods


N of patients		Group description		Methods		
			<i>Fusobacterium</i> spp.	<i>F. nucleatum</i>	Overall survival analysis	LINE-1 and miR-137
81	Total number of patients with GC included in the study (N-GC and T-GC)		X	X	X	X
80*	Total number of patients with available <i>F. nucleatum</i> status		X	X	X	X
27	Total number of patients with CRC included in the study (N-CRC and T-CRC)		X	X		
18	Patients with normal gastric mucosa (N)		X	X		
17	Patients with chronic non-atrophic gastritis (CNAG)		X	X		
9	Patients with atrophic gastritis with and without intestinal metaplasia (AG/IM)		X	X		

* one T-GC sample was lost during analysis


Supplementary Table S2: Primer sequences

Name	Primer sequence		Annealing temperature
Prostaglandin transporter (PGT) ¹¹	F	5'-ATC CCC AAA GCA CCT GGT TT-3' (20 bp)	59°C
	R	5'-AGA GGC CAA GAT AGT CCT GGT AA-3' (23 bp)	
	Probe	5'-CCA TTC ATG TCC TCA TCT C-3' (19 bp)	
<i>Fusobacterium spp.</i> ⁴¹	F:	5'-GGA TTT ATT GGG CGT AAA GC-3' (20 bp)	59°C
	R:	5'-GGC ATT CCT ACAAAT ATC TAC GAA-3' (24 bp)	
	Probe:	5'-CTC TAC ACT TGT AGT TCC G-3' (19 bp)	
<i>F. nucleatum</i> ⁹	F	5'-TGG TGT CAT TCT TCC AAA AAT ATC A-3' (25 bp)	54°C
	R	5'-AGA TCA AGA AGG ACA AGT TGC TGAA-3' (25 bp)	
	Probe	5'-ACT TTA ACT CTA CCA TGT TCA-3' (21 bp)	


Supplementary Figure S1 A




B



C




D



Supplementary Figure S1. Relative abundance of *Fusobacterium* spp. and *F. nucleatum* in colorectal and gastric cancer patients. (A) Relative abundance of *Fusobacterium* spp. in N-CRC (n=26) and T-CRC (n=24). (B) Relative abundance of *Fusobacterium* spp. in N-GC (n=78) and T-GC (n=80). (C) Relative abundance of *F. nucleatum* in N-CRC (n=25) and T-CRC (n=26). (D) Relative abundance of *F. nucleatum* in N-GC (n=79) and T-GC (n=80). Relative abundance is presented as $2^{\Delta Ct}$ values normalized to PGT. Undetectable values were set to the lowest measurable normalized value. Mann-Whitney-test was used for statistical analysis of two groups and Kruskal-Wallis test for more than two groups.

Supplementary Figure S2



Supplementary Figure S2. Analysis of *Fusobacterium* spp. and *F. nucleatum* abundance in relation to *H. pylori* status in controls and chronic gastritis patients. *H. pylori* positive group includes the patients with CNAG, AG/IM while *H. pylori* negative groups includes also the control group. Mann-Whitney-test was used for statistical analysis.